Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The targeting protein of serine/threonine protein phosphatase 5 (
PPP5C
) has been reported to be present in various malignancies. However, its functional role in pancreatic cancer (PC) remains unknown. In the present study, the function of
PPP5C
in PC cells treated with the first-line drug gemcitabine (GEM) was investigated. Short hairpin (sh)RNA targeting
PPP5C
was constructed to knockdown
PPP5C
in PANC-1 cells. Cell cycle and apoptosis analyses were performed in order to investigate the mechanisms underlying the effects induced by
PPP5C
silencing combined with GEM treatment. Western blot analysis was applied to detect the expression of certain key regulators of cell apoptosis in PANC-1 cells treated with GEM. shRNA against
PPP5C
effectively suppressed the proliferation of PANC-1 cells treated with GEM. Additionally, cell cycle analysis indicated that
PPP5C
knockdown resulted in a higher number of PANC-1 cells treated with GEM in G
0
/G
1
phase arrest. Knockdown of
PPP5C
increased the expression of associated apoptotic markers, including cleaved caspase 3, poly (ADP-ribose) polymerase and phosphorylated (p)-p53. In addition, the combination of treatment with GEM and
PPP5C
silencing significantly increased the apoptosis of PANC-1 cells by affecting the expression levels of p-
c-Jun
N-terminal kinases and p-p38. The present study suggests that
PPP5C
may be a potential target for the treatment of PC and that it may enhance the gemcitabine sensitivity of PC cells.
...
PMID:Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells
in vitro
. 2980 15
